Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases.
http://www.cannabis-med.org/studies/…w.php?s_id=180
Intractable nausea and vomiting due to gastrointestinal mucosal metastases
http://www.cannabis-med.org/studies/…ow.php?s_id=35 The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21807457
Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB(1) receptors: a keratinocyte-dependent effect. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21298280
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action (full – 2012) http/www.biomedcentral.com/1471-2407/12/92
Revisiting CB1 Receptor as Drug Target in Human Melanoma. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22447182
Cannabinoid receptor 2 is upregulated in melanoma. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/23361273
Anticancer activity of anandamide in human cutaneous melanoma cells. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24041928
Calcium regulation by temperature-sensitive transient receptor potential channels in human uveal melanoma cells. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24084605
CB2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC4057719/
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24576779
http://www.cannabis-med.org/studies/…w.php?s_id=180
Intractable nausea and vomiting due to gastrointestinal mucosal metastases
http://www.cannabis-med.org/studies/…ow.php?s_id=35 The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21807457
Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB(1) receptors: a keratinocyte-dependent effect. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21298280
The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action (full – 2012) http/www.biomedcentral.com/1471-2407/12/92
Revisiting CB1 Receptor as Drug Target in Human Melanoma. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22447182
Cannabinoid receptor 2 is upregulated in melanoma. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/23361273
Anticancer activity of anandamide in human cutaneous melanoma cells. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24041928
Calcium regulation by temperature-sensitive transient receptor potential channels in human uveal melanoma cells. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24084605
CB2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC4057719/
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24576779